Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

• Main Authors: Miriam Alonso-García (Author), Amparo Sánchez-Gastaldo (Author), Miguel A. Muñoz-Fuentes (Author), Sonia Molina-Pinelo (Author), Laura Boyero (Author), Johana Cristina Benedetti (Author), Reyes Bernabé-Caro (Author)
• Format: Book
• Published: MDPI AG, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared...